FR11C0033I2 - CORRECTION OF DUPUYTREN’S CONTRACTURE - Google Patents

CORRECTION OF DUPUYTREN’S CONTRACTURE

Info

Publication number
FR11C0033I2
FR11C0033I2 FR11C0033C FR11C0033C FR11C0033I2 FR 11C0033 I2 FR11C0033 I2 FR 11C0033I2 FR 11C0033 C FR11C0033 C FR 11C0033C FR 11C0033 C FR11C0033 C FR 11C0033C FR 11C0033 I2 FR11C0033 I2 FR 11C0033I2
Authority
FR
France
Prior art keywords
dupuytren
contracture
correction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0033C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advance Biofactures Corp
Original Assignee
Advance Biofactures Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advance Biofactures Corp filed Critical Advance Biofactures Corp
Publication of FR11C0033I1 publication Critical patent/FR11C0033I1/fr
Application granted granted Critical
Publication of FR11C0033I2 publication Critical patent/FR11C0033I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
FR11C0033C 1997-03-27 2011-08-18 CORRECTION OF DUPUYTREN’S CONTRACTURE Active FR11C0033I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/826,015 US6086872A (en) 1997-03-27 1997-03-27 Amelioration of dupuytren's disease
FR9803320A FR2772273B1 (en) 1997-03-27 1998-03-18 CORRECTION OF DUPUYTREN CONTRACT

Publications (2)

Publication Number Publication Date
FR11C0033I1 FR11C0033I1 (en) 2011-09-23
FR11C0033I2 true FR11C0033I2 (en) 2012-03-16

Family

ID=25245473

Family Applications (2)

Application Number Title Priority Date Filing Date
FR9803320A Expired - Lifetime FR2772273B1 (en) 1997-03-27 1998-03-18 CORRECTION OF DUPUYTREN CONTRACT
FR11C0033C Active FR11C0033I2 (en) 1997-03-27 2011-08-18 CORRECTION OF DUPUYTREN’S CONTRACTURE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR9803320A Expired - Lifetime FR2772273B1 (en) 1997-03-27 1998-03-18 CORRECTION OF DUPUYTREN CONTRACT

Country Status (8)

Country Link
US (2) US6086872A (en)
AU (1) AU733208B2 (en)
DE (1) DE19813748A1 (en)
DK (1) DK177324B1 (en)
FR (2) FR2772273B1 (en)
GB (1) GB2323530B (en)
NO (1) NO981388L (en)
SE (1) SE522723C2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
GB0306165D0 (en) * 2003-03-18 2003-04-23 Delta G Ltd Medical treatment
MX2007008764A (en) * 2005-01-21 2007-10-19 Advance Biofactures Corp Methods for treating adhesive capsulitis.
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
ITPD20050207A1 (en) * 2005-07-07 2007-01-08 Fidia Farmaceutici NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENAS IN THE TOPIC TREATMENT OF WOUNDS, BURNS AND ULCERS
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US20080233614A1 (en) * 2007-02-13 2008-09-25 Cranenburgh Rocky M Production of recombinant collagenases colg and colh in escherichia coli
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (en) * 2008-03-06 2013-05-11 Halozyme Inc In vivo temporal control of activatable matrix-degrading enzymes
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
US8702654B2 (en) 2009-03-25 2014-04-22 John M. Agee Treatment of carpal tunnel syndrome by injection of the flexor retinaculum
WO2012056044A1 (en) * 2010-10-30 2012-05-03 Imperial Innovations Ltd Treatment for dupuytren's disease
US10119131B2 (en) 2011-03-16 2018-11-06 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
ES2690568T3 (en) 2011-07-20 2018-11-21 Mediwound, Ltd. Bromelain proteolytic extract for the treatment of connective tissue disorders
GB201119089D0 (en) 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders
ES2968836T3 (en) 2012-01-12 2024-05-14 Endo Global Ventures Clostridium histolyticum enzyme
EP2852403B1 (en) * 2012-04-30 2018-03-07 Elastomics AB Methods for modification of tissues
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (en) 2014-01-15 2014-04-30 上海交通大学 Collagenase thermoresponsive hydrogel and preparation method and application of hydrogel
IL301796A (en) 2017-03-01 2023-05-01 Endo Ventures Ltd Method for assessing and treating cellulite
WO2018183582A2 (en) * 2017-03-28 2018-10-04 Endo Ventures Limited Improved method of producing collagenase
EP4045078A1 (en) 2019-10-15 2022-08-24 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US5173295A (en) * 1990-10-05 1992-12-22 Advance Biofactures Of Curacao, N.V. Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase

Also Published As

Publication number Publication date
AU5966198A (en) 1998-10-01
AU733208B2 (en) 2001-05-10
FR2772273A1 (en) 1999-06-18
DK40398A (en) 1998-09-28
USRE39941E1 (en) 2007-12-18
GB2323530B (en) 2001-10-10
SE9800806L (en) 1998-09-28
FR11C0033I1 (en) 2011-09-23
NO981388L (en) 1998-09-28
US6086872A (en) 2000-07-11
GB2323530A (en) 1998-09-30
DK177324B1 (en) 2013-01-07
SE9800806D0 (en) 1998-03-12
DE19813748A1 (en) 1998-10-01
NO981388D0 (en) 1998-03-26
GB9805050D0 (en) 1998-05-06
SE522723C2 (en) 2004-03-02
FR2772273B1 (en) 2003-04-25

Similar Documents

Publication Publication Date Title
FR11C0033I2 (en) CORRECTION OF DUPUYTREN’S CONTRACTURE
PT1032396E (en) STERILIZATION OF GLUCOCORTICOESTEROIDS
BR9800705A (en) Polymerization of cyclosiloxanes
DE69613368T2 (en) CHINAZOLIN DERIVATIVES
DE69613369T2 (en) CHINAZOLIN DERIVATIVES
DE69613367T2 (en) CHINAZOLIN DERIVATIVES
DE69536015D1 (en) Quinazolinone derivatives
FI973816A0 (en) Polypropen med Hoeg smaeltstyrka
PT907364E (en) PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERTACAO
PT868183E (en) INJECTABLE FORMULATIONS OF QUINOLONE
PT1028718E (en) FORMULATION OF PROLONGED LIBERATION
DK1300129T3 (en) Implant vial
PT921125E (en) DERIVATIVES OF 1,38-TRIAZA-ESPIRO 4,5 DECAN-4-ONA
FI973229A (en) New pharmaceutical composition
NO996545D0 (en) Treatment of aluminum slag
DE69805974T2 (en) 5-AROYLNAPHTHALINE DERIVATIVES
DE69710305T2 (en) Derivatives of 4-vinyl-4'-alpha-hydroxyethyl-biphenyl
KR970016291U (en) dumbbell
FR2766727B1 (en) EXERCISER
BR9704770A (en) Derivatives of 1-carba- (detia) -cephalosporin
DE69804179D1 (en) Photosensitive composition
ID29414A (en) TREATMENT OF DEPRESSION
ID21264A (en) IMPROVEMENT OF HIGH-POWERFUL PCI
SE9704040D0 (en) Dynamic dumbbell
BR9605659A (en) Set of goggles